Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 8.70
Ask: 9.50
Change: -0.15 (-1.62%)
Spread: 0.80 (9.195%)
Open: 9.25
High: 9.25
Low: 9.10
Prev. Close: 9.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Apr 2018 12:43

RNS Number : 8024L
Scancell Holdings Plc
23 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SCANCELL HOLDINGS PLC

 

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Hygea vct plc

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

18 April 2018

6. Date on which issuer notified (DD/MM/YYYY):

20 April 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.5%

0%

3.5%

374,469,098

Position of previous notification (if

applicable)

4.2%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

13,149,730

 

3.5%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Hygea vct plc

3.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

London, England

Date of completion

18 April 2018

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFVLSDIVFIT
Date   Source Headline
18th Apr 201811:05 amRNSSecond Price Monitoring Extn
18th Apr 201811:00 amRNSPrice Monitoring Extension
18th Apr 20187:00 amRNSProposed Placing, Subscription and Open Offer
18th Apr 20187:00 amRNSTechnology acquired from University of Nottingham
3rd Apr 20187:00 amRNSManufacturing agreement with The PolyPeptide Group
16th Feb 201811:30 amRNSScancell to present at the Calculus Investor Forum
15th Feb 20187:15 amRNSHardman Res. - Validating multiple opportunities
15th Feb 20187:00 amRNSCollaboration agreement with ISA Pharmaceuticals
12th Feb 20187:00 amRNSPublication highlights potential of SCIB1 therapy
9th Feb 20187:00 amRNSEuropean patent application allowed for grant
8th Feb 20187:00 amRNSScancell member of team shortlisted for CRUK award
1st Feb 20187:00 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSHalf-year Report
9th Jan 20187:00 amRNSScancell to collaborate with BioNTech
14th Dec 20177:00 amRNSScancell and CRUK to advance cancer immunotherapy
11th Oct 20179:44 amRNSResult of AGM
10th Oct 20177:00 amRNSDirectorate Change
14th Sep 20177:00 amRNSNotice of AGM
13th Sep 20177:00 amRNSFinal Results
11th Sep 20177:00 amRNSPresents Moditope Data at Immunotherapy Conference
29th Aug 20177:00 amRNSOncimmune and Scancell Present Autoantibodies Data
11th Jul 20177:00 amRNSContinued Progress on SCIB1
26th Jun 20177:00 amRNSDNA ImmunoBody Patent Granted in Europe
22nd May 201712:59 pmRNSHolding(s) in Company
19th May 20172:47 pmRNSHolding(s) in Company
19th May 20177:00 amRNSHolding(s) in Company
11th May 201712:09 pmRNSResults of Placing
11th May 20177:00 amRNSProposed Placing to Raise up to £5.0 million
13th Apr 201712:39 pmRNSChange of Registered Office
20th Mar 20177:00 amRNSImmuno-Oncology Summit Europe 2017
13th Mar 20177:15 amRNSHardman Research: SCIB development update
1st Mar 20177:00 amRNSHolding(s) in Company
31st Jan 20177:00 amRNSInterim Results
30th Jan 20177:00 amRNSPartnership to Advance Lung Cancer Clinical Trials
3rd Jan 201711:33 amRNSResearch Update - Amendment
3rd Jan 20177:00 amRNSResearch Update
14th Nov 20167:00 amRNSWorld Immunotherapy Congress and Biotech and Money
18th Oct 20165:42 pmRNSResults of AGM
10th Oct 20167:00 amRNSPreparing SCIB2 for clinical study in lung cancer
26th Sep 20167:15 amRNSHardman Report: New frontiers in T-cell activation
23rd Sep 20165:24 pmRNSNotice of AGM - Amendment
23rd Sep 20163:28 pmRNSNotice of AGM
16th Sep 20167:00 amRNSFinal Results
7th Sep 20167:00 amRNSNewsMakers in the Biotech Industry Conference
22nd Aug 20167:00 amRNSAppointment of Non-Executive Director
21st Jul 20167:00 amRNSEurogentec manufacturing agreement
20th Jul 20167:00 amRNSExtension to Ichor Commercial Option
13th Jul 20167:00 amRNSPeer-reviewed publication on Moditope® platform
6th Jul 20167:00 amRNSSCIB1 compelling survival data in melanoma
29th Jun 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.